Anton P Porsteinsson

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi Valproate therapy for agitation in dementia: open-label extension of a double-blind trial
    Anton P Porsteinsson
    Department of Psychiatry, Program in Neurobehavioral Therapeutics, University of Rochester Medical Center and Monroe Community Hospital, Tochester, NY 14620, USA
    Am J Geriatr Psychiatry 11:434-40. 2003
  2. ncbi Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial
    Anton P Porsteinsson
    Alzheimer s Disease Care, Research and Education Program, University of Rochester, School of Medicine and Dentistry, Rochester, NY 14620, USA
    Curr Alzheimer Res 5:83-9. 2008
  3. ncbi C145 as a short-latency electrophysiological index of cognitive compensation in Alzheimer's disease
    Robert M Chapman
    Department of Brain and Cognitive Sciences and Center for Visual Science at the University of Rochester, Rochester, NY 14627, USA
    J Alzheimers Dis 33:55-68. 2013
  4. ncbi Memantine in the treatment of mild-to-moderate Alzheimer's disease
    Kelly M Cosman
    University of Rochester School of Medicine, Alzheimer s Disease Care Research and Education Program AD CARE, Monroe Community Hospital, 435 East Henrietta Road, Rochester, NY 14620, USA
    Expert Opin Pharmacother 8:203-14. 2007
  5. ncbi Diagnosis of Alzheimer's disease using neuropsychological testing improved by multivariate analyses
    Robert M Chapman
    Brain and Cognitive Sciences and Center for Visual Science, University of Rochester, Rochester, NY 14627 0270, USA
    J Clin Exp Neuropsychol 32:793-808. 2010
  6. ncbi Depression predicts cognitive disorders in older primary care patients
    Lisa L Boyle
    Department of Psychiatry, Box PSYCH, University of Rochester Medical Center, 300 Crittenden Blvd, Rochester, NY 14642, USA
    J Clin Psychiatry 71:74-9. 2010
  7. ncbi Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders
    Louis A Profenno
    Department of Psychiatry, State University of New York Upstate Medical University, Syracuse, New York, USA
    Biol Psychiatry 67:505-12. 2010
  8. ncbi Divalproex sodium for the treatment of behavioural problems associated with dementia in the elderly
    Anton P Porsteinsson
    Department of Psychiatry, University of Rochester Medical Center, Monroe Community Hospital, Rochester, New York 14620, USA
    Drugs Aging 23:877-86. 2006
  9. ncbi Choosing treatment for Alzheimer's patients and their caregivers
    Lon S Schneider
    Geriatrics 58:3-18, 23; quiz 19-22. 2003
  10. ncbi A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease
    Joel E Streim
    Section on Geriatric Psychiatry, University of Pennsylvania, Philadelphia, PA 19104 3309, USA
    Am J Geriatr Psychiatry 16:537-50. 2008

Research Grants

  1. Depression in Alzheimer's Disease Study 2 (DIADS-2)
    Anton Porsteinsson; Fiscal Year: 2007

Detail Information

Publications12

  1. ncbi Valproate therapy for agitation in dementia: open-label extension of a double-blind trial
    Anton P Porsteinsson
    Department of Psychiatry, Program in Neurobehavioral Therapeutics, University of Rochester Medical Center and Monroe Community Hospital, Tochester, NY 14620, USA
    Am J Geriatr Psychiatry 11:434-40. 2003
    ..The authors describe an open-label extension of a double-blind, randomized, placebo-controlled study of divalproex sodium in 56 nursing home patients with agitation and dementia...
  2. ncbi Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial
    Anton P Porsteinsson
    Alzheimer s Disease Care, Research and Education Program, University of Rochester, School of Medicine and Dentistry, Rochester, NY 14620, USA
    Curr Alzheimer Res 5:83-9. 2008
    ..To evaluate the efficacy and safety of memantine in patients with mild to moderate Alzheimer's disease (AD) receiving cholinesterase inhibitor (ChEI) treatment...
  3. ncbi C145 as a short-latency electrophysiological index of cognitive compensation in Alzheimer's disease
    Robert M Chapman
    Department of Brain and Cognitive Sciences and Center for Visual Science at the University of Rochester, Rochester, NY 14627, USA
    J Alzheimers Dis 33:55-68. 2013
    ....
  4. ncbi Memantine in the treatment of mild-to-moderate Alzheimer's disease
    Kelly M Cosman
    University of Rochester School of Medicine, Alzheimer s Disease Care Research and Education Program AD CARE, Monroe Community Hospital, 435 East Henrietta Road, Rochester, NY 14620, USA
    Expert Opin Pharmacother 8:203-14. 2007
    ..However, the differences between treatment groups were not consistently significant. Two ongoing long-term trials are further investigating the efficacy of memantine in the treatment of mild-to-moderate AD...
  5. ncbi Diagnosis of Alzheimer's disease using neuropsychological testing improved by multivariate analyses
    Robert M Chapman
    Brain and Cognitive Sciences and Center for Visual Science, University of Rochester, Rochester, NY 14627 0270, USA
    J Clin Exp Neuropsychol 32:793-808. 2010
    ....
  6. ncbi Depression predicts cognitive disorders in older primary care patients
    Lisa L Boyle
    Department of Psychiatry, Box PSYCH, University of Rochester Medical Center, 300 Crittenden Blvd, Rochester, NY 14642, USA
    J Clin Psychiatry 71:74-9. 2010
    ..To investigate whether depression is independently associated with increased risk of incident dementia or cognitive disorder not otherwise specified (NOS) in an older primary care population...
  7. ncbi Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders
    Louis A Profenno
    Department of Psychiatry, State University of New York Upstate Medical University, Syracuse, New York, USA
    Biol Psychiatry 67:505-12. 2010
    ..Other risk factors may be obesity and diabetes and related disorders, which are highly prevalent...
  8. ncbi Divalproex sodium for the treatment of behavioural problems associated with dementia in the elderly
    Anton P Porsteinsson
    Department of Psychiatry, University of Rochester Medical Center, Monroe Community Hospital, Rochester, New York 14620, USA
    Drugs Aging 23:877-86. 2006
    ..Further research is needed to determine the optimal use of divalproex sodium for the treatment of neuropsychiatric symptoms of dementia and the long-term benefits, if any, of its use in this patient population...
  9. ncbi Choosing treatment for Alzheimer's patients and their caregivers
    Lon S Schneider
    Geriatrics 58:3-18, 23; quiz 19-22. 2003
  10. ncbi A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease
    Joel E Streim
    Section on Geriatric Psychiatry, University of Pennsylvania, Philadelphia, PA 19104 3309, USA
    Am J Geriatr Psychiatry 16:537-50. 2008
    ..To evaluate the efficacy and safety of aripiprazole treatment for psychotic symptoms associated with Alzheimer disease (AD)...
  11. ncbi Design of Depression in Alzheimer's Disease Study-2
    Barbara K Martin
    Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    Am J Geriatr Psychiatry 14:920-30. 2006
    ....
  12. ncbi Clinical application of operationalized criteria for 'Depression of Alzheimer's Disease'
    Paul B Rosenberg
    Division of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Int J Geriatr Psychiatry 20:119-27. 2005
    ..Criteria for the diagnosis of dAD have been proposed previously...

Research Grants1

  1. Depression in Alzheimer's Disease Study 2 (DIADS-2)
    Anton Porsteinsson; Fiscal Year: 2007
    ..The predictive validity of defining depression in AD using a symptom scale or each of these syndromes will be assessed longitudinally against the various study outcomes, and against efficacy of response to antidepressant treatment. ..